Clinical Trial Update: Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers [Phase 2]

View source ↗

Summary

Phase 2 study completed assessing GlaxoSmithKline's MenC-TT and Hib-MenC-TT (Meningitec) vaccines in healthy toddlers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Hib-MenC-TT (Haemophilus influenzae type b and meningococcal C conjugate vaccine with tetanus toxoid carrier protein)
• MenC-TT (Meningococcal C conjugate vaccine with tetanus toxoid carrier protein)
• Meningitec (Meningococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED